Cargando…
Neutrophil Gelatinase Associated Lipocalin (NGAL) – a biomarker of renal dysfunction in patients with liver cirrhosis: Do we have enough proof?
Rationale. Renal dysfunction has a serious impact on the natural evolution of liver cirrhosis. Treatment and prognosis may be improved if an early diagnosis could be established, and specific therapeutic interventions would be applied. Although RIFLE and AKIN classifications have been successfully i...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Carol Davila University Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4564045/ https://www.ncbi.nlm.nih.gov/pubmed/26361506 |
_version_ | 1782389368660426752 |
---|---|
author | Firu, SG Streba, CT Firu, D Tache, DE Rogoveanu, I |
author_facet | Firu, SG Streba, CT Firu, D Tache, DE Rogoveanu, I |
author_sort | Firu, SG |
collection | PubMed |
description | Rationale. Renal dysfunction has a serious impact on the natural evolution of liver cirrhosis. Treatment and prognosis may be improved if an early diagnosis could be established, and specific therapeutic interventions would be applied. Although RIFLE and AKIN classifications have been successfully implemented in the clinical practice of Nephrology and Intensive Care Units, these did not provide major improvements in patients with liver cirrhosis. In the last decade, various biomarkers of kidney injury have been assessed, and Neutrophil Gelatinase-Associated Lipocalin (NGAL) is one of the most promising and most studied novel biomarker. Objective. To offer a brief evaluation on current data on the utility of this biomarker in patients with liver cirrhosis. Methods and results. We have searched through current literature and analyzed all significant full text articles on this topic. Discussions. NGAL and other new kidney injury molecules may be useful in patients with liver cirrhosis, particularly in identifying structural kidney dysfunction, but larger validation studies to confirm this observation are needed. Abbreviations: ADQI = Acute Dialysis Quality Initiative, AKI = acute kidney injury, AKIN = Acute Kidney Injury Network, ATN = acute tubular necrosis, CKD = chronic kidney disease, Cys C = cystatin C, GFR = glomerular filtration rate, HRS = hepatorenal syndrome, IAC = International Ascites Club, IL-18 = interleukin-18, KIM-1 = kidney injury molecule-1, L-FABP = liver-type fatty acid-binding protein, LT = liver transplantation, MDRD6 = Modification of Diet in Renal Disease 6, NAG = N-acetyl-β-D-glucosaminidase, NGAL = Neutrophil Gelatinase-Associated Lipocalin, pi-GST = pi-glutathione S-transferase, PRA = prerenal azotemia, RBP = retinol binding protein, RRT = renal replacement therapies, SCr = serum creatinine, SLKT = simultaneous liver and kidney transplant, UO = urine output, γ-GT = γ-glutamyl transpeptidase |
format | Online Article Text |
id | pubmed-4564045 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Carol Davila University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-45640452015-09-10 Neutrophil Gelatinase Associated Lipocalin (NGAL) – a biomarker of renal dysfunction in patients with liver cirrhosis: Do we have enough proof? Firu, SG Streba, CT Firu, D Tache, DE Rogoveanu, I J Med Life Reviews Rationale. Renal dysfunction has a serious impact on the natural evolution of liver cirrhosis. Treatment and prognosis may be improved if an early diagnosis could be established, and specific therapeutic interventions would be applied. Although RIFLE and AKIN classifications have been successfully implemented in the clinical practice of Nephrology and Intensive Care Units, these did not provide major improvements in patients with liver cirrhosis. In the last decade, various biomarkers of kidney injury have been assessed, and Neutrophil Gelatinase-Associated Lipocalin (NGAL) is one of the most promising and most studied novel biomarker. Objective. To offer a brief evaluation on current data on the utility of this biomarker in patients with liver cirrhosis. Methods and results. We have searched through current literature and analyzed all significant full text articles on this topic. Discussions. NGAL and other new kidney injury molecules may be useful in patients with liver cirrhosis, particularly in identifying structural kidney dysfunction, but larger validation studies to confirm this observation are needed. Abbreviations: ADQI = Acute Dialysis Quality Initiative, AKI = acute kidney injury, AKIN = Acute Kidney Injury Network, ATN = acute tubular necrosis, CKD = chronic kidney disease, Cys C = cystatin C, GFR = glomerular filtration rate, HRS = hepatorenal syndrome, IAC = International Ascites Club, IL-18 = interleukin-18, KIM-1 = kidney injury molecule-1, L-FABP = liver-type fatty acid-binding protein, LT = liver transplantation, MDRD6 = Modification of Diet in Renal Disease 6, NAG = N-acetyl-β-D-glucosaminidase, NGAL = Neutrophil Gelatinase-Associated Lipocalin, pi-GST = pi-glutathione S-transferase, PRA = prerenal azotemia, RBP = retinol binding protein, RRT = renal replacement therapies, SCr = serum creatinine, SLKT = simultaneous liver and kidney transplant, UO = urine output, γ-GT = γ-glutamyl transpeptidase Carol Davila University Press 2015 /pmc/articles/PMC4564045/ /pubmed/26361506 Text en ©Carol Davila University Press http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Reviews Firu, SG Streba, CT Firu, D Tache, DE Rogoveanu, I Neutrophil Gelatinase Associated Lipocalin (NGAL) – a biomarker of renal dysfunction in patients with liver cirrhosis: Do we have enough proof? |
title | Neutrophil Gelatinase Associated Lipocalin
(NGAL) – a biomarker of renal dysfunction in patients
with liver cirrhosis: Do we have enough proof?
|
title_full | Neutrophil Gelatinase Associated Lipocalin
(NGAL) – a biomarker of renal dysfunction in patients
with liver cirrhosis: Do we have enough proof?
|
title_fullStr | Neutrophil Gelatinase Associated Lipocalin
(NGAL) – a biomarker of renal dysfunction in patients
with liver cirrhosis: Do we have enough proof?
|
title_full_unstemmed | Neutrophil Gelatinase Associated Lipocalin
(NGAL) – a biomarker of renal dysfunction in patients
with liver cirrhosis: Do we have enough proof?
|
title_short | Neutrophil Gelatinase Associated Lipocalin
(NGAL) – a biomarker of renal dysfunction in patients
with liver cirrhosis: Do we have enough proof?
|
title_sort | neutrophil gelatinase associated lipocalin
(ngal) – a biomarker of renal dysfunction in patients
with liver cirrhosis: do we have enough proof? |
topic | Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4564045/ https://www.ncbi.nlm.nih.gov/pubmed/26361506 |
work_keys_str_mv | AT firusg neutrophilgelatinaseassociatedlipocalinngalabiomarkerofrenaldysfunctioninpatientswithlivercirrhosisdowehaveenoughproof AT strebact neutrophilgelatinaseassociatedlipocalinngalabiomarkerofrenaldysfunctioninpatientswithlivercirrhosisdowehaveenoughproof AT firud neutrophilgelatinaseassociatedlipocalinngalabiomarkerofrenaldysfunctioninpatientswithlivercirrhosisdowehaveenoughproof AT tachede neutrophilgelatinaseassociatedlipocalinngalabiomarkerofrenaldysfunctioninpatientswithlivercirrhosisdowehaveenoughproof AT rogoveanui neutrophilgelatinaseassociatedlipocalinngalabiomarkerofrenaldysfunctioninpatientswithlivercirrhosisdowehaveenoughproof |